Home Alexion: 2 Global Drug Rollouts, But Upside Already Priced In
 

Keywords :   


Alexion: 2 Global Drug Rollouts, But Upside Already Priced In

2015-12-06 11:18:40| Biotech - Topix.net

Alexion is highly overvalued, even assuming best case peak sales projections of $1B for Strensiq, $1B for Kanuma, and $5B for Soliris. Payer risk for high-priced drugs isn't going away and orphan drug companies can't expect to keep getting a free pass.

Tags: in global drug priced

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
18.05Eastern North Pacific Tropical Weather Outlook
18.05Atlantic Tropical Weather Outlook
18.05Producers to be paid grid premiums for AngusLink beef scores
18.05This Week in Agribusiness, May 18, 2024
18.05This Week in Agribusiness, May 18, 2024
18.05Unpaid carers being forced to repay 250m to DWP
18.05Weekly Recap: Hempel, Axalta, KANSAI HELIOS Top This Weeks Stories
18.05Eastern North Pacific Tropical Weather Outlook
More »